 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
3 News |  |
- LY2599506 (PSN 010) / Eli Lilly
Enrollment change, Combination therapy, Monotherapy: A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 24, 2011
P2, N=38, Terminated, Sponsor: Eli Lilly and Company
N=27 --> 38
- LY2599506 (PSN 010) / Eli Lilly
Enrollment change: A Study of LY2599506 in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 24, 2011
P2, N=78, Terminated, Sponsor: Eli Lilly and Company
N=27 --> 38 N=40 --> 78